Preventing medication errors in cancer chemotherapy

American Journal of Health-System Pharmacy

Volumn 53, Issue 7, 1996, Pages 737-745

  Cohen, Michael R ^a   Anderson, Roger W ^b   Attilio, Richard M ^c   Green, Laurence ^d   Muller, Raymond J ^e   Pruemer, Jane M ^f  

^a INSTITUTE FOR SAFE MEDICATION PRACTICES   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c LEHIGH VALLEY HOSPITAL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antineoplastic agents; Communication; Dosage; Drug information; Education; Errors, medication; Guidelines; Industry, pharmaceutical; Institute for Safe Medication Practices; Neoplasms; Nomenclature; Nurses; Organizations; Patient education; Pharmacists; Physicians

Indexed keywords

ANTINEOPLASTIC AGENT; SILVER;

CANCER CHEMOTHERAPY; CLINICAL PHARMACY; DRUG DOSE; DRUG INFORMATION; DRUG THERAPY; EDUCATION PROGRAM; HEALTH CARE PERSONNEL; HUMAN; INTERPERSONAL COMMUNICATION; PATIENT EDUCATION; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STANDARDIZATION;

EID: 0029930318     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.7.737     Document Type: Review

References (56)

1. Knox RA. Response is slow to deadly mixups. Too little done to avert cancer drug errors. Boston Globe. 1995; Jun 26:29,33.
2. United Kingdom Joint Council for Clinical Oncology. Quality control in cancer chemotherapy. Managerial and procedural aspects. Oxford, England: Royal College of Physicians of London; 1994.
3. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. JAMA. 1995; 274:35-43.
4. Peters BG, Wilson AL, Lunik MC et al. Certification program in antineoplastic drug preparation for pharmacy technicians and pharmacists. Am J Hosp Pharm. 1994; 51:1902-6.
5. Melamed AJ, Nacov CG, Muller RJ. Antineoplastic agents: some preparation and handling considerations. Pharm Pract News. 1986; 13:18-19.
6. Aricó M, Nespoli L, Porta F et al. Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol. 1990; 18:261-3.
7. Wang Chin JM, Muller RJ, Lucarelli CD. A pharmacy intervention program: recognizing pharmacy's contribution to improving patient care. Hosp Pharm. 1995; 30:120,123-6,129-30.
8. Finley RS, Balmer CM, Dozier N et al. Concepts in oncology therapeutics. A self-instructional course. Bethesda, MD: American Society of Hospital Pharmacists; 1991.
9. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. Middleton, CT: Appleton & Lange; 1994.
10. Perry MC, ed The chemotherapy sourcebook. Baltimore: Williams & Wilkins; 1992.
11. Flannelly BP, Gregory RE, Kim Y et al. Guide for the administration and use of cancer chemotherapeutic agents. Pharm Pract News. 1995; 22(8):47-51.
12. Lopez TM, Hagemeister FB, McLaughlin P et al. Small non-cleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990; 8:615-22.
13. Cohen MR. Misprint in journal article leads to vincristine overdose. Hosp Pharm. 1994; 29:294,302.
14. Chu G, Mantin R, Shen Y-M et al. Massive cisplatin overdose by accidental substitution for carboplatin. Cancer. 1993; 73:3707-14.
15. Pike IM, Arbus MH. Cisplatin overdosage. Am J Hosp Pharm. 1992; 49:1668. Letter.
16. 2 of cisplatin. Am J Med. 1989; 86:624-5. Letter.
17. Jost LM. Overdose with melphalan (Alkeran): symptoms and treatment. A review. Onkologie. 1990; 13:96-101.
18. Hachimi-Idrissi S, Schots R, DeWolf D et al. Reversible cardiopathy after accidental overdose of mitoxantrone. Pediatr Hematol Oncol. 1993; 10:35-40.
19. Zaniboni A, Simoncini E, Marpicati P et al. Severe delayed neurotoxicity after accidental high-dose nitrogen mustard. Am J Hematol. 1988; 27:305. Letter.
20. Conter V, Rabbone ML, Jankovic M et al. Overdose of vinblastine in a child with Langerhans' cell histiocytosis: toxicity and salvage therapy. Pediatr Hematol Oncol. 1991; 8:165-9.
21. Kaufman IA, Kung FH, Koenig HM et al. Overdosage with vincristine. J Pediatr. 1976; 89:671-4.
22. Kosmidis HV, Bouhoutsou DO, Varvoutsi MC et al. Vincristine overdose: experience with 3 patients. Pediatr Hematol Oncol. 1991; 8:171-8.
23. Maeda K, Ueda M, Ohtaka H et al. A massive dose of vincristine. Jpn J Clin Oncol. 1987; 17:247-53.
24. Kim IS, Gratwohl A, Stebler C et al. Accidental overdose of multiple chemotherapeutic agents. Korean J Intern Med. 1989; 4:171-3.
25. DeVita V, Hellman S, Rosenberg M, eds. Cancer. Principles and practice of oncology. 4th ed. Philadelphia: Lippincott: 1993.
26. Cohen MR. Cisplatin vial seals to carry message on dose limits. Hosp Pharm. 1995; 30:538-9.
27. Al Fawaz IM. Fatal myeloencephalopathy due to intrathecal vincristine administration. Ann Trop Paediatr. 1992; 12:339-42.
28. Bain PG, Lantos PL, Djurovic V et al. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol. 1991; 238:230-4.
29. Gaidys WG, Dickerman JD, Walters CL et al. Intrathecal vincristine. Report of a fatal case despite CNS washout. Cancer. 1983; 52:799-801.
30. Manelis J, Freudlich E, Ezekiel E et al. Accidental intrathecal vincristine administration. Report of a case. J Neurol. 1982; 228:209-13.
31. Schochet SS Jr, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol. 1968; 27:645-58.
32. Shepherd DA, Steuber CP, Starling KA et al. Accidental intrathecal administration of vincristine. Med Pediatr Oncol. 1978; 5:85-8.
33. Slyter H, Liwnicz B, Herrick MK et al. Fatal myeloencephalopathy caused by intrathecal vincristine. Neurology. 1980; 30:867-71.
34. Williams ME, Walker AN, Bracikowski JP et al. Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeuric error. Cancer. 1983; 51:2041-7.
35. Bleck TP, Jacobsen J. Prolonged survival following the inadvertent intrathecal administration of vincristine: clinical and electrophysiologic analyses. Clin Neuropharmacol. 1991; 14: 457-62.
36. Dyke RW. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med. 1989; 321:1270-1.
37. Zaragoza MR, Ritchey ML, Walter A, Neurourologic consequences of accidental intrathecal vincristine: a case report. Med Pediatr Oncol. 1995; 24:61-2.
38. Cohen MR. Warning: vincristine practice standard must be followed by pharmacists and others. Hosp Pharm. 1995; 30:740-1.
39. Lafolie P, Liliemark J, Bjork O et al. Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine. Med Toxicol Adverse Drug Exp. 1988; 3:248-52.
40. Ettinger LJ. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer. 1982; 50:444-50.
41. Davis NM, Cohen MR, Teplitsky B. Look-alike and sound-alike drug names: the problem and the solution. Hosp Pharm. 1992; 27:95-8,102-5,108-10.
42. Cohen MR. "Adria," a dangerous abbreviation for Adriamycin, looks like Aredia. Hosp Pharm. 1994; 9:141,158.
43. Cohen MR. Safety alert - overdoses of Platinol (cisplatin) and Paraplatin (carboplatin). Hosp Pharm. 1992; 27:991-2.
44. Sullivan P, Heaney J. Hospital admits giving wrong drug to sick child. Boston Herald. 1995; Apr 6:7.
45. Slimovitz R. Thoughts on a medical disaster. Am J Health-Syst Pharm. 1995; 52:1464-5. Letter.
46. Cohen MR, Davis NM. Developing safe and effective preprinted physician's order forms. Hosp Pharm. 1992; 27:508, 513, 528.
47. American Society of Hospital Pharmacists. Guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50:305-14.
48. Di Domizio G, Cohen MR. Medication errors: who's at fault and who's counting. Med Malpract Law Strategy. 1995; 12(5):1-4.
49. Cyclophosphamide package insert. Princeton, NJ: Bristol-Myers Squibb; 1995.
50. Cohen MR. Cancer chemotherapy needs improved quality assurance. Hosp Pharm. 1995; 30:258-9.
51. Enck RE, Bennett JM. Inadvertent chlorambucil overdose in adult. N Y State J Med. 1977; 9:1480-1.
52. Hörnsten P, Sundman-Engberg B, Gahrton G et al. CCNU toxicity after an overdose in a patient with Hodgkin's disease. Scand J Haematol. 1983; 31:9-14.
53. Hadjiyanni M, Valianatou K, Tzilianos M et al. Prolonged thrombocytopenia after procarbazine "overdose." Eur J Cancer. 1992; 28A:1299. Letter.
54. Muller RJ, Agre P. Patient education: a multidisciplinary approach to influence patient compliance. Top Hosp Pharm Manage. 1991; 10(4):50-8.
55. Grossman SA, Piantodosi S, Cvahay C. Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J Clin Oncol. 1994; 12:2211-5.
56. Knox RA. Doctor's orders killed cancer patient. Boston Globe. 1995; Mar 23:1,16.